Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).

Basit Öğe Kaydı
dc.contributor.authorAbulkhair, O.
dc.contributor.authorUslu, R.
dc.contributor.authorSezgin, C.
dc.contributor.authorBueyuekberber, S.
dc.contributor.authorDarwish, T.
dc.contributor.authorIsikdogan, A.
dc.contributor.authorGumus, M.
dc.date.accessioned2024-04-24T17:12:18Z
dc.date.available2024-04-24T17:12:18Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.doi10.1158/0008-5472.SABCS12-OT1-1-08
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.urihttps://doi.org/10.1158/0008-5472.SABCS12-OT1-1-08
dc.identifier.urihttps://hdl.handle.net/11468/17925
dc.identifier.volume72en_US
dc.identifier.wosWOS:000209704900083
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherAmer Assoc Cancer Researchen_US
dc.relation.ispartofCancer Research
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleClinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).en_US
dc.titleClinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu